2023
Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial
Morais A, Locascio J, Sansing L, Lamb J, Nagarkatti K, Imai T, van Leyen K, Aronowski J, Koenig J, Bosetti F, Lyden P, Ayata C, Bosetti F, Koenig J, Lyden P, Lamb J, Nagarkatti K, Hess D, Kamat P, Khan M, Dhandapani K, Arbab A, Siddiqui S, Smith C, Nisar M, Leira E, Chauhan A, Dhanesha N, Patel R, Kumskova M, Thedens D, Wang K, Ayata C, Morais A, Imai T, Qin T, Jin X, Erdogan T, Yu L, Mandeville J, Kimberly W, Whittier J, Lo E, Arai K, Van Leyen K, Sansing L, Hyder F, Mihailovic J, Sanganahalli B, Diaz-Perez S, Velazquez S, Beatty H, Johnson C, Herman A, Boisserand L, Immakavar E, Koehler R, Dawson T, Dawson V, Shi Y, Avery B, Lannon S, Bibic A, Akhter K, Karuppagounder S, Aronowski J, McCullough L, Obertas L, Goh A, Huang S, Chauhan A. Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial. Stroke 2023, 54: 620-631. PMID: 36601951, PMCID: PMC9870939, DOI: 10.1161/strokeaha.122.040638.Peer-Reviewed Original ResearchConceptsTotal anesthesia durationAnesthesia durationIndependent predictorsMultivariable analysisClinical trialsTransient focal cerebral ischemiaFocal cerebral ischemiaCerebral blood flowLaser Doppler flowCentralized randomizationModified intentionTreat populationExperimental strokeCerebral ischemiaDoppler flowRodent modelsMCAOBlood flowNetwork trialFlow dropPreclinical trialsMouse cohortsStudy designTrialsTrial onset
2022
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions
Magid-Bernstein J, Girard R, Polster S, Srinath A, Romanos S, Awad IA, Sansing LH. Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circulation Research 2022, 130: 1204-1229. PMID: 35420918, PMCID: PMC10032582, DOI: 10.1161/circresaha.121.319949.Peer-Reviewed Original ResearchConceptsMechanism of injuryIntracerebral hemorrhageUltra-early hemostatic therapyInflammatory brain injuryCurrent treatment strategiesIron-induced injuryAnticoagulant useHemostatic therapyHemorrhagic strokeHypertension managementICH therapySurgical managementHigh morbidityPrimary preventionFunctional outcomeICH managementBrain injuryClinical trialsTreatment strategiesPrognostic biomarkerDevastating formDisease pathobiologyInjuryInvasive surgeryOxidative stressThe Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results
Lyden PD, Bosetti F, Diniz MA, Rogatko A, Koenig JI, Lamb J, Nagarkatti KA, Cabeen RP, Hess DC, Kamat PK, Khan MB, Wood K, Dhandapani K, Arbab AS, Leira EC, Chauhan AK, Dhanesha N, Patel RB, Kumskova M, Thedens D, Morais A, Imai T, Qin T, Ayata C, Boisserand LSB, Herman AL, Beatty HE, Velazquez SE, Diaz-Perez S, Sanganahalli BG, Mihailovic JM, Hyder F, Sansing LH, Koehler RC, Lannon S, Shi Y, Karuppagounder SS, Bibic A, Akhter K, Aronowski J, McCullough LD, Chauhan A, Goh A, Siddiqui S, Sheth K, Matouk C, Cruz C, Zhou J, Dawson V, Dawson T, Liang J, van Zijl P, Zeiler S, Taylor Kimberly W, Erdogan T, Yu L, Mandeville J, Whittier J. The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results. Stroke 2022, 53: 1802-1812. PMID: 35354299, PMCID: PMC9038686, DOI: 10.1161/strokeaha.121.038047.Peer-Reviewed Original ResearchConceptsPreclinical assessmentStroke treatmentCandidate treatmentMiddle cerebral artery occlusion (MCAO) surgeryClinical stroke trialsSuccessful stroke treatmentInclusion/exclusion criteriaStroke clinical trialsClinical trial designYoung male animalsComorbid diseasesOcclusion surgeryCerebral ischemiaNeurological disabilityComorbid conditionsStroke trialsProtocol adherenceBlinded assessmentSuch therapyClinical trialsClinical studiesExclusion criteriaTrial designAged animalsOutcome assessment
2021
Admission Hemoglobin Levels Are Associated With Functional Outcome in Spontaneous Intracerebral Hemorrhage
Acosta JN, Leasure AC, Kuohn LR, Both CP, Petersen NH, Sansing LH, Matouk CC, Testai F, Langefeld CD, Woo D, Kamel H, Murthy SB, Qureshi A, Mayer SA, Sheth KN, Falcone GJ. Admission Hemoglobin Levels Are Associated With Functional Outcome in Spontaneous Intracerebral Hemorrhage. Critical Care Medicine 2021, 49: 828-837. PMID: 33591003, PMCID: PMC8611893, DOI: 10.1097/ccm.0000000000004891.Peer-Reviewed Original ResearchConceptsAdmission hemoglobin levelsHemoglobin levelsNontraumatic intracerebral hemorrhageIntracerebral hemorrhageHematoma volumePoor outcomeHematoma expansionIntracerebral hemorrhage patientsPredictors of outcomeSpontaneous intracerebral hemorrhageIndividual patient dataHigher hemoglobin levelsAdmission hematoma volumeExposure of interestDose-response analysisAdmission hemoglobinRankin ScalePrimary outcomeHemorrhage patientsFunctional outcomeRepeat CTClinical trialsObservational studyHemorrhage sizeBetter outcomesLongitudinal transcriptomics define the stages of myeloid activation in the living human brain after intracerebral hemorrhage
Askenase MH, Goods BA, Beatty HE, Steinschneider AF, Velazquez SE, Osherov A, Landreneau MJ, Carroll SL, Tran TB, Avram VS, Drake RS, Gatter GJ, Massey JA, Karuppagounder SS, Ratan RR, Matouk CC, Sheth KN, Ziai WC, Parry-Jones AR, Awad IA, Zuccarello M, Thompson RE, Dawson J, Hanley DF, Love JC, Shalek AK, Sansing LH, Barrer S, MacKenzie L, Jonczak K, Bussinger P, Nakaji P, Wright S, Honea N, Zomorodi A, James M, Yeh E, Galicich W, Bergman T, France K, Leiphart J, Ramesh S, Brennan T, Huang J, Ziai W, White M, Camarata P, Abraham M, Gorup J, Reimer R, Freeman W, Williams C, Edwards E, Pollack A, Terry J, Shoen A, Jahromi B, Maas M, Yip B, Amidei C, Muñoz L, Lopez G, Holtz R, Gupta G, Rybinnik I, Moccio M, Lovick D, Brion B, Titus K, Jallo J, Rincon F, Pigott K, Boyden L, Dougherty J, Harrigan M, Miller D, Nelson L, Thompson G, Rajajee V, Pandey A, Ball R, Carlson A, Tran H, Alchbli A, James R, Jerde A, Taussky P, Ansari S, Neate C, Martinez J, Letsinger J, Fagatele L, Eaquinto C, Matouk C, Sheth K, Sansing L, Ryall L, Kunze K, Mampre D, Jasak S, Abdul-Rahim A, Abou-Hamden A, Abraham M, Ahmed A, Alba C, Aldrich E, Ali H, Altschul D, Amin-Hanjani S, Anderson C, Anderson D, Ansari S, Antezana D, Ardelt A, Arikan F, Awad R, Baguena M, Baker A, Barrer S, Barzo P, Becker K, Bergman T, Betz J, Bistran-Hall A, Boström A, Braun J, Brindley P, Broaddus W, Brown R, Buki A, Bulters D, Camarata P, Cao B, Cao Y, Carhuapoma J, Carlson A, Caron J, Carrion-Penagos J, Chalela J, Chang T, Chicoine M, Chorro I, Chowdhry S, Cobb C, Corral L, Csiba L, Davies J, Dawson J, Díaz A, Derdeyn C, Diringer M, Dlugash R, Dodd R, Ecker R, Economas T, Enriquez P, Ezer E, Fan Y, Feng H, Franz D, Freeman W, Fusco M, Galicich W, Gandhi D, Gelea M, Goldstein J, Gonzalez A, Grabarits C, Greenberg S, Gregson B, Gress D, Gu E, Gupta G, Hall C, Hanley D, Hao Y, Harnof S, Harrigan M, Hernandez F, Hoesch R, Hoh B, Houser J, Hu R, Huang J, Huang Y, Hussain M, Insinga S, Jadhav A, Jaffe J, Jahromi B, Jallo J, James M, James R, Janis S, Jankowitz B, Jeon E, Jichici D, Jonczak K, Jonker B, Karlen N, Kase C, Keric N, Kerz T, Kitagawa R, Knopman J, Koenig C, Krishnamurthy S, Kumar A, Kureshi I, Laidlaw J, Lakhanpal A, Lane K, Latorre J, LeDoux D, Lees K, Leifer D, Leiphart J, Lenington S, Li Y, Lopez G, Lovick D, Lumenta C, Luo J, Maas M, MacDonald J, MacKenzie L, Madan V, Majkowski R, Major O, Malhorta R, Malkoff M, Mangat H, Maswadeh A, Matouk C, Mayo S, McArthur K, McBee N, McCaul S, Medow J, Mendelow A, Mezey G, Mighty J, Miller D, Mitchell P, Mohan K, Money P, Mould W, Muir K, Muñoz L, Nakaji P, Nee A, Nekoovaght-Tak S, Nyquist P, O’Kane R, Okasha M, O'Kelly C, Ostapkovich N, Pandey A, Parry-Jones A, Patel H, Perla K, Pollack A, Polster S, Pouratian N, Quinn T, Rajajee V, Reddy K, Rehman M, Reimer R, Rincon F, Rosenblum M, Rybinnik I, Sanchez B, Sansing L, Sarabia R, Schneck M, Schuerer L, Schul D, Schweitzer J, Seder D, Seyfried D, Sheth K, Spiotta A, Stadnik A, Stechison M, Sugar E, Szabo K, Tamayo G, Tanczos K, Taussky P, Teitelbaum J, Terry J, Testai F, Thomas K, Thompson C, Thompson G, Thompson R, Torner J, Tran H, Tucker K, Ullman N, Ungar L, Unterberg A, Varelas P, Vargas N, Vatter H, Venkatasubramanian C, Vermillion K, Vespa P, Vollmer D, Wang W, Wang Y, Wang Y, Wen J, Whitworth L, Willis B, Wilson A, Wolfe S, Wrencher M, Wright S, Xu Y, Yanase L, Yenokyan G, Yi X, Yu Z, Ziai W, Zomorodi A, Zuccarello M. Longitudinal transcriptomics define the stages of myeloid activation in the living human brain after intracerebral hemorrhage. Science Immunology 2021, 6 PMID: 33891558, PMCID: PMC8252865, DOI: 10.1126/sciimmunol.abd6279.Peer-Reviewed Original ResearchConceptsIntracerebral hemorrhageHypoxia-inducible factorMyeloid activationBrain injuryImmune responseAnti-inflammatory circuitsSubtypes of strokeAnti-inflammatory factorsInflammatory gene expressionPositive patient outcomesMonocytes/macrophagesDynamics of inflammationAcute sterile injuryLongitudinal transcriptional profilingHuman brainNeurological recoveryMyeloid responseProinflammatory profileImmune resolutionPatient cohortImmune factorsClinical trialsPatient outcomesSterile injuryProstaglandin E
2019
Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes
Murthy SB, Biffi A, Falcone GJ, Sansing LH, Torres Lopez V, Navi BB, Roh DJ, Mandava P, Hanley DF, Ziai WC, Kamel H, Rosand J, Sheth KN, Butcher K, Davis S, Gregson B, Lees K, Lyden P, Mayer S, Muir K, Steiner T. Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes. Stroke 2019, 50: 3057-3063. PMID: 31895618, PMCID: PMC6941441, DOI: 10.1161/strokeaha.119.025972.Peer-Reviewed Original ResearchConceptsAntiplatelet therapyIntracerebral hemorrhageFunctional outcomeHematoma locationCause mortalityMajor disabilityVirtual International Stroke Trials Archive databaseCox proportional regression analysisConclusions Antiplatelet therapyRecurrent intracerebral hemorrhageProportional regression analysisPoor functional outcomeRandomized clinical trialsSpontaneous intracerebral hemorrhagePaucity of dataAntiplatelet medicationsStroke RegistryThromboembolic riskHazard ratioMulticenter cohortPrimary outcomeMedian timeICH patientsClinical trialsMeta-analyzed data
2009
Who will participate in acute stroke trials?
Kasner SE, Del Giudice A, Rosenberg S, Sheen M, Luciano JM, Cucchiara BL, Messé S, Sansing LH, Baren JM. Who will participate in acute stroke trials? Neurology 2009, 72: 1682-1688. PMID: 19433742, PMCID: PMC2683644, DOI: 10.1212/wnl.0b013e3181a55fbe.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAttitude to HealthBiomedical ResearchCaregiversClinical Trials as TopicCultureData CollectionFemaleHumansInformed ConsentMaleMental CompetencyMiddle AgedPatient CompliancePatient Education as TopicPhysician-Patient RelationsProspective StudiesRisk AssessmentRisk-TakingStrokeConceptsAcute treatment trialsAcute strokeTreatment trialsClinical trialsAcute stroke treatment trialsAcute stroke clinical trialsMean age 63Stroke treatment trialsVascular risk factorsMinority of patientsAcute stroke trialsStroke clinical trialsNovel therapeutic agentsStroke severityClinical factorsPrimary outcomeStroke trialsAcute trialProspective surveyTrial interventionRisk factorsStroke typeHigh incidenceAge 63Patients